Search

Foundation Fighting Blindness and ProQR enter into a partnership to develop QR-421a for Usher syndrome type 2A, targeting mutations in exon 13 of the causative USH2A gene.

Initial pipeline programs with liver delivery to address Cholestatic Diseases targeting NTCP and Cardiovascular Disease targeting B4GALT1 Development of Axiomer® RNA base editing technology platform continues across multiple therapeutic areas Stre

LEIDEN, The Netherlands & CAMBRIDGE, Mass., Feb. 27, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.

New agreement supports the discovery and development of additional assets directed toward high conviction targets utilizing ProQR’s Axiomer technology

LEIDEN, The Netherlands, Aug. 08, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.

Key updates

Received CTA authorization for Phase 1 trial of lead program AX-0810, targeting NTCP for cholestatic diseasesInitiating Phase 1 study of AX-0810 in healthy volunteers, with initial safety, tolerability, and PK data from Cohort 1 expected by year-end, and target engagemen

AX-0810 targeting NTCP for cholestatic diseases to be first ProQR Axiomer™ RNA editing program to enter the clinic Company to host virtual Investor and Analyst Event in December to highlight translational data and clinical plans for AX-0810, as well as AX-1412, targeting

Key program features and updates:

LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 22, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.